In a xenogeneic mouse injected with the MOLM-13 cell line, CD4 CAR-T cells exhibit an 80%–100% of disease control, while CD4 NK-CAR achieved a 98% tumor reduction up to day 9 of treatment. Here, CD4 is linked to neoplasm.